Looks to me like the current USFDA trials are set more specifically for "Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough", NCT04318704. The Exclusion Criteria section has lots of limits and the Inclusion Criteria section does not mention COVID and appears to me to be IPF specific. Novotech efforts for Ifenprodil in Austrailia also seem to be directed at IPF and ALI, IMO.
The Korean Phase 2 trials appear to me to be more directed toward COVID-19 thru MOHW, South Korea. Ifenprodil is an approved drug in South Korea for other indications and is being tested for Repurposing, IMO. They have a specific Korean Lead investigator/sponsor/University led with Dr. Dong.
" The Phase 2 human trials will consist of 40 patients during a 4-week trial and will be testing the efficacy of Ifenprodil in infected patients with Covid-19. Dr. Dong Sik Jung, Professor in the Division of Infectious Disease of Dong-A University Hospital in Busan, South Korea will be the lead principal investigator overseeing the trials and patient enrollment for Phase 2 clinical trials is set to take place on May 8th, 2020. The CEO of AGN Christopher Moreau stated, “This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program”.
!! Watch 4/23Video mins 4:00 to 5:30 for Recruitment, heck watch it all again...!!
I hope that the Canada Trial approvals, with their Phase 2b/3 plans, work out and then move QUICKLY. Canada seems to present the best of all possibilities for Algernon Investors.
The Algernon management team's use of our CRO and their many cunsultant's help, also as discussed in the 4/23 Video, shows the many paths they are developing now just for NP-120. Several layers of confirmations and data from around the World!.
My respect for the efforts and building acheivements of our team. Yes, "this has a different feel"..GLTA...
